EP Patent

EP2234986A2 — Sulfamides as zap-70 inhibitors

Assigned to Cellzome Ltd · Expires 2010-10-06 · 16y expired

What this patent protects

The invention relates to compounds of formula (I). Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immuno logically-mediated diseases. The invention also relates to pharmaceutic…

USPTO Abstract

The invention relates to compounds of formula (I). Said compounds are useful as inhibitors of ZAP-70 for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immuno logically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.

Drugs covered by this patent

Patent Metadata

Patent number
EP2234986A2
Jurisdiction
EP
Classification
—
Expires
2010-10-06
Drug substance claim
No
Drug product claim
No
Assignee
Cellzome Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.